AstraZeneca, FibroGen can't agree on roxadustat's path forward in chronic kidney disease after FDA rejection

In the months since the FDA's high-profile rejection for oral anemia drug roxadustat, AstraZeneca and FibroGen have been working to chart a potential path forward for the med in chronic kidney disease (CKD). But the two partners are now split on what that path might look like, leaving dim prospects for a refiling.